252 related articles for article (PubMed ID: 17475330)
1. FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions.
Daniel C; Sartory NA; Zahn N; Schmidt R; Geisslinger G; Radeke HH; Stein JM
Mol Immunol; 2007 Jul; 44(13):3305-16. PubMed ID: 17475330
[TBL] [Abstract][Full Text] [Related]
2. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile.
Daniel C; Sartory NA; Zahn N; Radeke HH; Stein JM
J Pharmacol Exp Ther; 2008 Jan; 324(1):23-33. PubMed ID: 17911375
[TBL] [Abstract][Full Text] [Related]
3. The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice.
Deguchi Y; Andoh A; Yagi Y; Bamba S; Inatomi O; Tsujikawa T; Fujiyama Y
Oncol Rep; 2006 Oct; 16(4):699-703. PubMed ID: 16969482
[TBL] [Abstract][Full Text] [Related]
4. FTY720 suppresses CD4+CD44highCD62L- effector memory T cell-mediated colitis.
Fujii R; Kanai T; Nemoto Y; Makita S; Oshima S; Okamoto R; Tsuchiya K; Totsuka T; Watanabe M
Am J Physiol Gastrointest Liver Physiol; 2006 Aug; 291(2):G267-74. PubMed ID: 16574986
[TBL] [Abstract][Full Text] [Related]
5. The new low calcemic vitamin D analog 22-ene-25-oxa-vitamin D prominently ameliorates T helper cell type 1-mediated colitis in mice.
Daniel C; Radeke HH; Sartory NA; Zahn N; Zuegel U; Steinmeyer A; Stein J
J Pharmacol Exp Ther; 2006 Nov; 319(2):622-31. PubMed ID: 16914561
[TBL] [Abstract][Full Text] [Related]
6. FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells.
Daniel C; Sartory N; Zahn N; Geisslinger G; Radeke HH; Stein JM
J Immunol; 2007 Feb; 178(4):2458-68. PubMed ID: 17277153
[TBL] [Abstract][Full Text] [Related]
7. Oxazolone-induced murine model of ulcerative colitis.
Wang X; Ouyang Q; Luo WJ
Chin J Dig Dis; 2004; 5(4):165-8. PubMed ID: 15612886
[TBL] [Abstract][Full Text] [Related]
8. 3,3'-Diindolylmethane alleviates oxazolone-induced colitis through Th2/Th17 suppression and Treg induction.
Huang Z; Jiang Y; Yang Y; Shao J; Sun X; Chen J; Dong L; Zhang J
Mol Immunol; 2013 Apr; 53(4):335-44. PubMed ID: 23085552
[TBL] [Abstract][Full Text] [Related]
9. B cells that produce immunoglobulin E mediate colitis in BALB/c mice.
Hoving JC; Kirstein F; Nieuwenhuizen NE; Fick LC; Hobeika E; Reth M; Brombacher F
Gastroenterology; 2012 Jan; 142(1):96-108. PubMed ID: 21983080
[TBL] [Abstract][Full Text] [Related]
10. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice.
Nofer JR; Bot M; Brodde M; Taylor PJ; Salm P; Brinkmann V; van Berkel T; Assmann G; Biessen EA
Circulation; 2007 Jan; 115(4):501-8. PubMed ID: 17242282
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut.
Caruso R; Sarra M; Stolfi C; Rizzo A; Fina D; Fantini MC; Pallone F; MacDonald TT; Monteleone G
Gastroenterology; 2009 Jun; 136(7):2270-9. PubMed ID: 19505427
[TBL] [Abstract][Full Text] [Related]
12. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L
Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441
[TBL] [Abstract][Full Text] [Related]
13. Helminth infection enhances disease in a murine TH2 model of colitis.
Hunter MM; Wang A; McKay DM
Gastroenterology; 2007 Apr; 132(4):1320-30. PubMed ID: 17408663
[TBL] [Abstract][Full Text] [Related]
14. The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells.
Müller H; Hofer S; Kaneider N; Neuwirt H; Mosheimer B; Mayer G; Konwalinka G; Heufler C; Tiefenthaler M
Eur J Immunol; 2005 Feb; 35(2):533-45. PubMed ID: 15657952
[TBL] [Abstract][Full Text] [Related]
15. Treatment with FTY720 during the induction or effector phase suppresses the development of experimental allergic conjunctivitis in mice.
Sumi T; Fukushima A; Nishino K; Fukuda K; Kumagai N; Nishida T; Ueno H
Cell Biol Int; 2009 Apr; 33(4):534-41. PubMed ID: 19230848
[TBL] [Abstract][Full Text] [Related]
16. FTY720 suppresses the development of colitis in lymphoid-null mice by modulating the trafficking of colitogenic CD4+ T cells in bone marrow.
Fujii T; Tomita T; Kanai T; Nemoto Y; Totsuka T; Sakamoto N; Nakamura T; Tsuchiya K; Okamoto R; Watanabe M
Eur J Immunol; 2008 Dec; 38(12):3290-303. PubMed ID: 19009523
[TBL] [Abstract][Full Text] [Related]
17. FTY720-induced conversion of conventional Foxp3- CD4+ T cells to Foxp3+ regulatory T cells in NOD mice.
Sun Y; Wang W; Shan B; Di J; Chen L; Ren L; Li W; Li DJ; Lin Y
Am J Reprod Immunol; 2011 Nov; 66(5):349-62. PubMed ID: 21623989
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease.
Abad C; Martinez C; Juarranz MG; Arranz A; Leceta J; Delgado M; Gomariz RP
Gastroenterology; 2003 Apr; 124(4):961-71. PubMed ID: 12671893
[TBL] [Abstract][Full Text] [Related]
19. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
Chiba K
Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
[TBL] [Abstract][Full Text] [Related]
20. FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs.
Hofmann M; Brinkmann V; Zerwes HG
Int Immunopharmacol; 2006 Dec; 6(13-14):1902-10. PubMed ID: 17161343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
